EUVIMEDEUVIMED entdecken
Crossref

Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability

Seth Simpson, Kelli C Dominick, Craig A Erickson, Martine Lamy

Journal of Autism and Developmental Disorders · 2026

DOI: 10.1007/s10803-024-06372-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Autism and Developmental Disorders, 2026. Verfasst von Seth Simpson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shodair Children's Hospital, 2755 Colonial Dr., Helena, MT, 59601, USA. Hauptthemen laut MEDLINE: Paliperidone Palmitate, Intellectual Disability, Antipsychotic Agents, Irritable Mood. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This retrospective chart review examines the safety, tolerability and effectiveness of long acting injectable paliperidone palmitate (P-LAI) targeting irritability in twenty-six youth and transition-aged individuals with autism spectrum disorder (ASD) and/or intellectual disability (ID) over a 3-year window. Clinical response was evaluated via prospectively assigned Clinical Global Impressions Severity (CGI-S) and Improvement (CGI-I) scales as well as number of hospital presentations. P-LAI was well tolerated with only 3 patients stopping P-LAI due to side effects. The average duration of P-LAI treatment was 21.1 months. Difficulty with medication compliance was the most common reason for initiating P-LAI. There was a statistically significant improvement in CGI-I, CGI-S and hospital visits and no change in BMI noted. Given the potential difficulty of medication administration in this population, this evidence of safety, tolerability as well as preliminary data supporting effectiveness is an important addition to the literature regarding psychopharmacologic management of irritability in youth with ASD and ID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Paliperidone PalmitateIntellectual DisabilityAntipsychotic AgentsIrritable MoodAutism Spectrum DisorderHumansMaleFemaleChildAdolescentRetrospective StudiesTreatment OutcomeChild, Preschool

Stichwörter der Autor:innen

AntipsychoticAutismChildrenIntellectual disabilityLong acting injectablePaliperidone

Substanzen

Paliperidone PalmitateAntipsychotic Agents

Autor:innen und Institutionen

  • Shodair Children's Hospital, 2755 Colonial Dr., Helena, MT, 59601, USA.
  • Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA. Kelli.dominick@cchmc.org.
  • Division of Child and Adolescent Psychiatry (MLC 4002), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Kelli.dominick@cchmc.org.
  • Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Division of Child and Adolescent Psychiatry (MLC 4002), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

Zitieren

APA

Simpson, S., Dominick, K. C., Erickson, C. A., & Lamy, M. (2026). Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-024-06372-9

Vancouver

Simpson S, Dominick KC, Erickson CA, Lamy M. Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability. Journal of Autism and Developmental Disorders. 2026. doi:10.1007/s10803-024-06372-9

BibTeX
@article{Simpson2026,
  author = {Simpson, Seth and Dominick, Kelli C and Erickson, Craig A and Lamy, Martine},
  title = {Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability},
  journal = {Journal of Autism and Developmental Disorders},
  year = {2026},
  doi = {10.1007/s10803-024-06372-9}
}
Kostenlos starten →